08:00 , Mar 12, 2001 |  BC Week In Review  |  Company News

Celltech Group, Pharmacia deal

The companies will co-develop and co-promote worldwide CCH's CDP 870 TNF-alpha humanized antibody fragment to treat rheumatoid arthritis (RA) and Crohn's disease. PHA will pay $50 million upfront to CCH, with additional payments of up...
08:00 , Mar 5, 2001 |  BC Extra  |  Company News

Pharmacia, Celltech in arthritis deal

PHA and Celltech (LSE:CCH; CLL) will co-develop and co-promote worldwide CCH's CDP 870 TNF-alpha humanized antibody fragment for rheumatoid arthritis (RA) and Crohn's disease. PHA will pay $50 million upfront to CCH, with additional payments...
08:00 , Dec 21, 1998 |  BC Week In Review  |  Company News

Searle, Kaken Pharmaceutical Co. Ltd. deal

Kaken will receive exclusive rights in Japan to Searle's Arthrotec , a non-steroidal anti-inflammatory compound that includes gastrointestinal mucosal protection against ulcers. Arthrotec was approved in 1997 to treat arthritis pain and inflammation. G.D. Searle...
08:00 , Dec 16, 1996 |  BC Week In Review  |  Company News

Monsanto agbio/veterinary/environmental news

Monsanto's board approved a plan to spin off the company's chemical businesses, resulting in a life sciences company and a chemical company, both to be publicly held and separately traded. The businesses that now comprise...